Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 70. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)
ArticleCitations
Paisan Ruamviboonsuk: saving sight in Thailand901
Vitamin D supplementation and mortality779
Empagliflozin in adults hospitalised with COVID-19: a (null) hypothesis for RECOVERY488
Madelung's disease in a rare 14th century Franco-Flemish woolen tapestry429
Metabolic non-communicable diseases in India: time to act398
Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer387
Ashley Grossman: finding a calling in neuroendocrinology382
Mark Atkinson: bringing two worlds together365
Vitamin D to prevent acute respiratory infections344
Action framework on healthy food: a way forward for the public sector320
Fetal growth patterns as early markers of fetal programming306
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals299
Implications of technology guidelines for low-income and middle-income countries282
Diabetes and the WHO Model List of Essential Medicines261
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions252
Dissection of type 2 diabetes: a genetic perspective251
The human factor226
Insulin for all: a hope yet to be realised218
May Ng: a lifetime commitment to children216
A framework for improving diabetes care in humanitarian emergencies216
Dulaglutide for erectile dysfunction in type 2 diabetes206
Tackling childhood obesity in low-socioeconomic status communities: what is the next step?185
A community-based, multi-level, multi-setting, multi-component intervention to reduce weight gain among low socioeconomic status Latinx children with overweight or obesity: The Stanford GOALS randomis177
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial176
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel176
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study175
New metrics to support diabetes education and advocacy168
Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK160
Data processing in the DMagic cluster randomised controlled trial159
Youth-onset type 2 diabetes among First Nations young people in northern Australia: a retrospective, cross-sectional study157
Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study152
Estimating the total incidence of type 1 diabetes in children and adolescents aged 0–19 years from 1990 to 2050: a global simulation-based analysis151
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial150
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records146
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study140
Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study138
Current insights and emerging trends in early-onset type 2 diabetes132
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial119
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial119
Sex steroids and the female brain across the lifespan: insights into risk of depression and Alzheimer's disease116
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial116
Challenges in implementing nationwide epidemiological studies on metabolic non-communicable diseases in low-income and middle-income countries112
Global diabetes incidence trends in young adults111
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p110
Association of age with gaps in diabetes-related care and hospitalisations from childhood to young adulthood in Quebec, Canada: a cohort study103
The growing global burden of thyroid cancer overdiagnosis102
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis102
Semaglutide for obesity: four STEPs forward, but more to come101
Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme99
Diabetes and the WHO Model List of Essential Medicines95
Big babies, small babies: metformin exposure in pregnancy94
Milestone achievement for global access to blood glucose meters and test strips93
People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action93
South Africa to produce insulin for Africa in 202491
Reducing sodium intake: step-by-step targets yield success87
What's preventing us from curbing the obesity crisis?85
Thought for food: a Cushing's syndrome enigma explained82
Progress in diabetes prevention or epidemiology—or both, or neither?81
Newer antidiabetic agents: at what price will they be cost effective?81
The growing clinical effect of SGLT2 inhibitors80
Mendelian randomisation and vitamin D: the importance of model assumptions78
Targeting RET-mutated thyroid and lung cancer in the personalised medicine era78
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes – Authors' reply77
Hot topics on insulin access: the issue of thermostability76
Banning diabetes blanket bans76
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale76
Gender disparities in publishing: from words to actions75
Anand Hardikar: a scientific nomad searching for the truth75
Post-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement73
The food system: hunger for change73
0.16298604011536